Comparative clinical effects and cost–effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To compare the clinical effects and cost–effectiveness of maximum androgen blockade (MAB), docetaxel to androgen deprivation therapy (Doc-ADT) and ADT alone for the treatment of patients with metastatic hormone-sensitive prostate cancer in China. Methods: A network meta-analysis and a Markov model were adopted for effectiveness and economic evaluation. Results: The hazard ratios of overall survival and progression-free survival were 0.782 and 0.628 for Doc-ADT versus ADT alone; 0.897 and 0.824 for MAB versus ADT alone. Doc-ADT was cost-effective compared with MAB and ADT alone, with an incremental cost–effectiveness ratio of CNY 96,848 and CNY 67,758 per quality-adjusted life year, respectively. MAB was cost-effective compared with ADT alone, with an incremental cost–effectiveness ratio of CNY 137,487 per quality-adjusted life year. Conclusion: Doc-ADT is likely the optimal option from the perspective of both clinical outcomes and economic considerations.
Supplementary Material
File (suppl_file.docx)
- Download
- 238.58 KB
References
Papers of special note have been highlighted as: • of interest
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
2.
Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am. J. Mens Health 12(6), 1807–1823 (2018).
3.
Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115–132 (2016).
4.
Han S, Zhang S, Chen W, Li C. Analysis of the status and trends of prostate cancer incidence in China. Chin. Clin. Oncol. 18(4), 330–334 (2013).
5.
Stokes ME, Ishak J, Proskorovsky I, Black LK, Huang Y. Lifetime economic burden of prostate cancer. BMC Health Serv. Res. 11(1), 349 (2011).
6.
Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65(2), 467–479 (2014).
7.
National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of prostate cancer (2018). www.nhc.gov.cn/
8.
NCCN Guidelines for Patients, Prostate Cancer, Version 1. 2016. 2018 (April 27) (2016). www.nccn.org/patients/guidelines/prostate/
9.
Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355(9214), 1491–1498 (2000).
10.
Sweeney C, Chen Y, Liu G et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Ann. Oncol. 27(Suppl. 6), vi243–vi265 (2016).
11.
Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015).
12.
James N, Mason M. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first survival results from STAMPEDE. J. Clin. Oncol. 33(33), 5001 (2015).
13.
Ye D. Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition. Chin. J. Surg. 56(9), 646–652 (2018).
14.
Liu GG, Vortherms SA, Hong X. China's health reform update. Ann. Rev. Public Health 38, 431–448 (2017).
15.
Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med. Res. Methodol. 10(1), 54 (2010).
• Provides the instruction and WinBUGS codes for network meta-analysis.
16.
Zalcberg J, Raghaven D, Marshall V, Thompson P. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate – an Australian multicentre trial. Br. J. Urol. 77(6), 865–869 (1996).
17.
Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339(15), 1036–1042 (1998).
18.
Akaza H, Hinotsu S, Usami M et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long‐term follow‐up of a Phase 3, double‐blind, randomized study for survival. Cancer 115(15), 3437–3445 (2009).
19.
Crawford ED, Blumenstein BA, Goodman PJ et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66, 1039–1044 (1990).
20.
Denis L, Keuppens F, Smith P et al. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur. Urol. 33(2), 144–151 (1998).
21.
Tyrrell CJ, Altwein J, Klippel F et al. Comparison of an LH–RH analogue (goeserelin acetate, ‘Zoladex’) with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized–trial. Eur. Urol. 37(2), 205–211 (2000).
22.
Gravis G, Boher J-M, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized Phase III GETUG-AFU15 trial. Eur. Urol. 70(2), 256–262 (2016).
• The reconstructed individual inpatient data of overall survival and progression-free survival were based on the survival analysis of Gravis 2016.
23.
James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163–1177 (2016).
24.
Craig BA, Black MA. Incremental cost–effectiveness ratio and incremental net-health benefit: two sides of the same coin. Expert Rev. Pharmacoecon. Outcomes Res. 1(1), 37–46 (2001).
25.
Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12(1), 9 (2012).
• Provides the methods and codes for reconstructing individual patient data from survival curve.
26.
Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. cost–effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff. Resour. Alloc. 16(1), 29 (2018).
27.
Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med. 367(7), 595–605 (2012).
28.
Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Medical Care 347–355 (2005).
29.
Aguiar Jr PN, Barreto CMN, Gutierres BDS, Tadokoro H, Lopes Jr GDL. Cost–effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. Einstein (São Paulo) 15(3), 349–354 (2017).
30.
Zheng H, Wen F, Wu Y, Wheeler J, Li Q. Cost–effectiveness analysis of additional docetaxel for metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy from a Chinese perspective. Eur. J. Cancer Care 26(6), e12505 (2017).
• A Chinese cost–effectiveness study that accesses the same metastatic hormone-sensitive prostate cancer population as ours, but draws a different conclusion.
Information & Authors
Information
Published In
Pages: 865 - 877
PubMed: 31476895
Copyright
© 2019 Wei Jiang. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 23 November 2018
Accepted: 15 May 2019
Published online: 3 September 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative clinical effects and cost–effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0133
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Zhou Han, Youli Xi, Jian Hu, Ye Wang, Huanyu Ni, Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China, Frontiers in Pharmacology, 10.3389/fphar.2025.1684966, 16, (2025).
- Yang Yang, Ya-Qing Chen, Long-Zhuan Huang, Yong Chen, Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer, Frontiers in Public Health, 10.3389/fpubh.2025.1680002, 13, (2025).
- Christopher G Fawsitt, Elaine Gallagher, Alka Singh, Hannah Baker, Edward Kayongo, Howard Thom, Noman Paracha, Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review, PharmacoEconomics, 10.1007/s40273-025-01532-w, 43, 11, (1323-1338), (2025).
- Cristóbal Ávila, Jaime González-Montero, Carlos I Rojas, Ravi A Madan, Mauricio Burotto, Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review, The Oncologist, 10.1093/oncolo/oyaf095, 30, 5, (2025).
- Juan Hong, Xiaohui Zeng, Wenjun Chen, Ziyuan Zhou, Yuming He, Jun Meng, Lihui Ouyang, Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation, Frontiers in Public Health, 10.3389/fpubh.2025.1574780, 13, (2025).
- Poucheok Pang, Baoying Tan, Jianwei Xuan, Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China, Intelligent Pharmacy, 10.1016/j.ipha.2023.05.001, 1, 2, (67-72), (2023).
- Olajide A. Adekunle, Enrique Seoane-Vazquez, Lawrence M. Brown, Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer, Journal of the American Pharmacists Association, 10.1016/j.japh.2022.12.019, 63, 3, (817-824.e3), (2023).
- Rémi Pelloux-Prayer, Thomas Bataillard, Antoine Thiery-Vuillemin, Alexandre Vincent, Philippe Fagnoni, Virginie Nerich, Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations, Clinical Genitourinary Cancer, 10.1016/j.clgc.2022.04.014, 20, 6, (594-602), (2022).
- Michaela C. Barbier, Yuki Tomonaga, Dominik Menges, Henock G. Yebyo, Sarah R. Haile, Milo A. Puhan, Matthias Schwenkglenks, Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer, PLOS ONE, 10.1371/journal.pone.0277282, 17, 11, (e0277282), (2022).
- Peng-Fei Zhang, Dan Xie, Qiu Li, Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis, Frontiers in Public Health, 10.3389/fpubh.2021.608375, 9, (2021).